Brookwood Investment Group LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA

Brookwood Investment Group LLC acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 16,569 shares of the company’s stock, valued at approximately $502,000.

Other large investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $39,000. Russell Investments Group Ltd. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $43,000. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $251,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $59.58 on Friday. The business has a fifty day simple moving average of $39.53 and a two-hundred day simple moving average of $32.07. Oruka Therapeutics, Inc. has a 1 year low of $7.14 and a 1 year high of $64.61. The company has a market capitalization of $2.95 billion, a price-to-earnings ratio of -32.03 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ORKA shares. Stifel Nicolaus increased their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Piper Sandler started coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective for the company. Barclays increased their price objective on Oruka Therapeutics from $50.00 to $78.00 and gave the company an “overweight” rating in a report on Tuesday. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Finally, Guggenheim reissued a “buy” rating and issued a $60.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $64.90.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joana Goncalves sold 7,641 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This represents a 18.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 23,765 shares of company stock valued at $849,575 in the last ninety days. Insiders own 24.69% of the company’s stock.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.